B. Nair

发表

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols

B. Barlogie, J. Shaughnessy, J. Sawyer, 2012, Leukemia.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

B. Barlogie, F. van Rhee, Y. Alsayed, 2012, Haematologica.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

T. Wilt, R. MacDonald, I. Rutks, 2001, The Cochrane database of systematic reviews.

Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols

B. Barlogie, J. Crowley, J. Szymonifka, 2009, British journal of haematology.

CONFUSION AND LIGHTHEADEDNESS RELATED TO CALCIUM CHANNEL BLOCKER TOXICITY

B. Nair, D. Chandra, Yogita Rochalani, 2015 .

TNF‐α inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature

P. Mehta, G. Raval, B. Nair, 2007 .

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

B. Barlogie, J. Shaughnessy, M. Dhodapkar, 2011 .

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, British journal of haematology.

Human Placenta‐Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone

B. Barlogie, J. Shaughnessy, J. Epstein, 2011, Stem cells.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

D. Campana, B. Barlogie, C. Rooney, 2015, Journal of immunotherapy.

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

D. Campana, B. Barlogie, C. Rooney, 2012 .

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

John Crowley, Pingping Qu, Bart Barlogie, 2011, Blood.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

David R Williams, Bart Barlogie, O. Stephens, 2010, Proceedings of the National Academy of Sciences.

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

B. Barlogie, Y. Alsayed, J. Crowley, 2013, Leukemia.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2010, Blood.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

B. Barlogie, J. Shaughnessy, M. Dhodapkar, 2014, Blood.

High-risk myeloma: when to transplant-or not.

C. Hofmeister, S. Lonial, F. Cavallo, 2014, Seminars in oncology.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

B. Barlogie, F. van Rhee, J. Crowley, 2012, Blood.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2010, Blood.

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012, Clinical Cancer Research.

variable in terms of both onset and duration in Total Therapy protocols Complete remission in multiple myeloma examined as time-dependent

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012 .

Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high‐risk gene expression profile

B. Barlogie, E. Anaissie, F. van Rhee, 2009, British journal of haematology.

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

B. Barlogie, J. Sawyer, F. van Rhee, 2015, Clinical case reports.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

B. Barlogie, E. Anaissie, J. Shaughnessy, 2011, Cancer.

TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature.

P. Mehta, G. Raval, B. Nair, 2007, American journal of hematology.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

B. Barlogie, E. Anaissie, J. Epstein, 2013, Haematologica.

Bilateral Pleural Effusions due to Pulmonary Manifestation of Multiple Myeloma

A. Agarwal, Meghana Bansal, Sandeep Singla, 2012 .

Predictive Biomarkers and Personalized Medicine Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR 3 C 1

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012 .

Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis

S. Atrash, J. Muzaffar, C. Westfall, 2012, The American journal of case reports.

Smoking cessation among patients in a cancer clinic: Evaluation of a novel, motivational stop-smoking pocket calendar

A. Sherman, P. Mehta, A. Safar, 2009, Journal of Cancer Education.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

D. Campana, B. Barlogie, C. Rooney, 2012 .

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

B. Barlogie, E. Anaissie, J. Epstein, 2013, Haematologica.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2010, Blood.